drugset / Trial / NCT00404586

Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber

NCT00404586

Phase 1 Completed 45 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

This study was designed to look at safety aspects and effects of intranasal doses of GW784568X on allergic rhinitis symptoms to develop this drug for its use in people who suffer with allergic rhinitis

Timeline

Start
2006-09-11
Primary completion
2007-01-16
Completion
2007-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject GW784568X Unknown 100 ug Intranasal
Subject GW784568X Unknown 200 ug Intranasal
Subject GW784568X Unknown 400 ug Intranasal
Background Fluticasone propionate Other / unclassified 200 ug Intranasal